Washington, D.C. 20549

Form 8-K


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): May 8, 2019  

Global Blood Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)

(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification Number)


171 Oyster Point Blvd., Suite 300, South San Francisco, CA 94080
(Address of Principal Executive Offices) (Zip Code)

(650) 741-7700
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 [   ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 [   ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 [   ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 [   ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [   ]


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [   ]


Securities registered pursuant to Section 12(b) of the Act:


Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareGBTThe NASDAQ Global Select Market



Item 2.02. Results of Operations and Financial Condition.

On May 8, 2019, Global Blood Therapeutics, Inc. announced recent business progress and its financial results for the first quarter ended March 31, 2019. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits 

Exhibit No. Description
99.1 Press Release, dated May 8, 2019, furnished herewith


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Global Blood Therapeutics, Inc.
Date: May 8, 2019By: /s/ Jeffrey Farrow        
  Jeffrey Farrow
  Chief Financial Officer
(Principal Financial Officer)



GBT Reports Recent Business Progress and First Quarter 2019 Financial Results

SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the first quarter ended March 31, 2019.

“With a goal of getting voxelotor to the sickle cell community as quickly as possible, our efforts in the first part of 2019 have focused on preparing to submit our New Drug Application (NDA) in the second half of this year and working with the U.S. Food and Drug Administration (FDA) on the details of our post-approval confirmatory transcranial doppler (TCD) study to demonstrate voxelotor’s impact on reducing stroke risk,” said Ted W. Love, M.D., president and chief executive officer of GBT. “We also look forward to sharing 24-week efficacy data from approximately 270 patients in our Phase 3 HOPE Study at an upcoming medical meeting. This 24-week efficacy data from the full patient cohort is what will be included in our NDA submission.”

Recent Business Progress



Financial Results for the Three Months Ended March 31, 2019
Cash, cash equivalents and marketable securities totaled $575.1 million at March 31, 2019, compared with $591.8 million at December 31, 2018. 

Net loss for the three months ended March 31, 2019, was $48.9 million compared with $41.6 million for the same period in 2018. Basic and diluted net loss per share for the three months ended March 31, 2019, was $0.87 compared with $0.87 for the same period in 2018. We expect our net loss to increase during 2019 as we expand our manufacturing efforts for voxelotor, commence the conduct of additional clinical studies of voxelotor in SCD, continue our existing SCD clinical trials and increase general and administrative (G&A) spending as we buildout our commercial infrastructure and prepare for the potential commercial launch of voxelotor in SCD.

Research and development (R&D) expenses for the three months ended March 31, 2019, were $34.5 million compared with $29.9 million for the same period in 2018. The increase in R&D expenses is primarily attributable to increased employee-related costs, including non-cash stock compensation, and increased consulting spend associated with NDA filing activities.  Total R&D stock-based compensation expense incurred for the three months ended March 31, 2019, was $4.0 million, compared with $3.0 million for the same period in 2018.

General and administrative (G&A) expenses for the three months ended March 31, 2019, were $18.1 million compared with $12.8 million for the same period in 2018. The increase in G&A expenses is primarily attributable to increased employee-related costs, including non-cash stock compensation, and increased level of spend associated with the buildout of our commercial infrastructure. Total G&A stock-based compensation expense incurred in the three months ended March 31, 2019, was $5.4 million, compared with $4.8 million for the same period in 2018.

About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing two therapies for the potential treatment of sickle cell disease, including its late-stage product candidate, voxelotor, as an oral, once-daily therapy. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about GBT’s anticipated public offering, anticipated use of proceeds and other statements containing the words “anticipate,” “planned,” “believe,” “forecast,” “estimated,” “expected,” and “intend,” among others. These forward-looking statements are based on GBT’s current expectations and actual results could differ materially. Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We intend these forward-looking statements, including statements regarding our plan to submit a rolling NDA for voxelotor under an accelerated regulatory approval pathway, the availability of, and sufficiency of our data to support, accelerated regulatory approval, the therapeutic potential and safety profile of voxelotor, including the potential to be a disease-modify therapy for SCD, our plan to initiate a TCD confirmatory study, our potential commercial launch, our ability to implement and complete our clinical development plans for voxelotor, our ability to engage in continued discussions with the FDA and the outcome of our discussions with the FDA, our ability to generate and report data from our ongoing and potential future studies of voxelotor (including data from patients enrolled in our Phase 3 HOPE Study, including the 24-week efficacy data from approximately 270 patients, and data in our ongoing Phase 2a HOPE-KIDS 1 Study), our plan to include this 24-week efficacy data in our NDA, regulatory review and actions relating to voxelotor, and the timing of these events, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, the risks that our clinical and preclinical development activities may be delayed or terminated for a variety of reasons, that results of clinical trials may be subject to differing interpretations, that regulatory authorities may disagree with our clinical development plans or require additional studies or data to support further clinical investigation of our product candidates, that drug-related adverse events may be observed in clinical development, and that data and results may not meet regulatory requirements or otherwise be sufficient for further development, regulatory review or approval, along with those risks set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


Condensed Consolidated Statements of Operations
 (In thousands, except share and per share amounts)

 Three Months Ended March 31,
 2019 2018
Operating expenses:   
Research and development$34,468  $29,944 
General and administrative18,055  12,751 
Total operating expenses52,523  42,695 
Loss from operations(52,523) (42,695)
Other income (expense):     
Interest income, net3,650  1,173 
Other expenses, net(50) (34)
Total other income, net3,600  1,139 
Net loss$(48,923) $(41,556)
Basic and diluted net loss per common share$(0.87) $(0.87)
Weighted-average number of shares used in computing basic and diluted net loss per common share56,231,587  47,770,023 


Condensed Consolidated Balance Sheets

(In thousands)

 March 31, 2019 December 31, 2018
Current assets:   
Cash and cash equivalents$156,836  $275,357 
Short-term marketable securities 300,431   202,177 
Prepaid expenses and other current assets 8,222   8,246 
Total current assets 465,489   485,780 
Property and equipment, net 13,090   14,981 
Long-term marketable securities 117,811   114,281 
Operating lease right-of-use assets 14,075    
Other assets 2,595   2,601 
Total assets$613,060
Liabilities and Stockholders’ Equity   
Current liabilities$
32,091  $
Operating lease liabilities, noncurrent 24,401    
Other liabilities, noncurrent 30   11,071 
Total liabilities 56,522   44,844 
Total stockholders’ equity 556,538   572,799 
Total liabilities and stockholders’ equity$613,060  $617,643 

Contact Information:
Stephanie Yao (investors and media)